Introduction
Marketed medications have to be safe and effective for their intended use. Any such use of drug products is submitted to rigorous scrutiny before marketing approval inform of in vitro studies, animal studies, clinical trials. These data provide specific labeling information, that is, approved indications for use, the appropriate dose and the specific populations for its use. [1] The exorbitant growth and use of pharmaceuticals are managed in most of the nations by a regulatory system which sharply divides use into licensed and unlicensed categories.
Drugs use confirming to the marketing label is known as labeled use. Off-label use is the use of pharmaceutical drugs for an unapproved indication, age group, dosage, or unapproved form of administration.
in unlicensed indication so another terminology given by few physicians is "nearly label" for example use of antidepressant fluoxetine in the case of maintenance therapy of recurrent depression. [3] Last decade has seen increased use of psychotropic medication. [4, 5] Unlicensed use of drugs in psychiatry setting is very common feature in all sub specialties as compared to license drugs. [6] [7] [8] This use of off-label drugs was supported by strong scientific evidence in only 4% of cases. [9] Most common mode of off-label prescribing in Psychiatry Department is unapproved indication, dose, altered population. [10, 11] Most commonly cited indication is depression, obsessive compulsive disorder, posttraumatic disorder, personality traits. [12] Prescribing of drugs in off label manner for nonapproved indication is mainly pharmaceutical companies driven as regulatory meshwork is more stringent and adding new indication will increase the patent value of newer congener drug. [13, 14] Some psychiatrists think that clinical trials on psychiatric patients is a rarity and particularly in both the extreme of ages. They all also felt that off-label prescribing is needed as more than 80% of the psychiatric diagnosis by DSM-IV have no Food and Drug Administration (FDA) approved medication. [15] Also for some drugs, randomized clinical trials data are not available for the use in resistant cases. But in last two decades, clinical trials have shoot up searching for new indications for already established psychiatric drugs, e.g., Duloxetine in neuropathic pain and gabapentin in anxiety and insomnia disorders. [16] Atypical antipsychotics are the leading among psychiatric drugs which are always queued for off-label prescribing so their use should be weighed against their cost, regulatory status, and incomplete nature of available evidence. [12] There is a paucity of reports or studies in India. Hence, this study was planned to evaluate off label drug use in patients attending Outpatient Department of Psychiatry.
Materials and Methods
A prospective, cross-sectional study was carried out in Psychiatric Outpatient Department of a Tertiary Care Teaching Hospital over a period of 1-year from October 1, 2012 to September 30, 2013. Approval from Institutional Ethics committee was obtained. All the patients attending the Psychiatric Outpatient Department and those who agreed to give consent during this period were enrolled in the study after obtaining the consent of patient or patient's guardian. Demographic data, complete clinical history, and complete prescription details were recorded in case record form. The prescription given to the patient including the drug prescribed, dose, frequency, and duration of the treatment was noted. British National Formulary (BNF)-2011 [17] was used as a reference source to identify off-label prescribing.
Statistical analyses
The data were analyzed by using SPSS version 21.0 ® IBM Corporation. Fischer's exact test was used to determine the significant difference between labeled and off-labeled prescriptions for different variables. Pearson correlation coefficient was used to determine the association of offlabel prescribing with age, number of drugs. P < 0.05 was considered as significant.
Result
Demographic and morbidity pattern [ Table 1 ] A total of 250 patients were included in the study with a mean age of 40.36 ± 12.31 years (range 4-70 years). Male patient's comprised 137 (54.8%) out of 250 patients. The most common diagnosis was major depressive disorder 101 (40.4%) followed by bipolar disorder 67 (26.8%), schizophrenia 50 (20%), obsessive compulsive disorder 7 (2.8%), and mania 5 (2%).
A total of 980 drugs were prescribed with mean number of drugs prescribed per patient 3.6 ± 1.42 (range 1-7). More than one psychotropic drug was used in 98% patients. Diazepam 117 (46.8%) was the most frequently prescribed drug followed by imipramine-57 (22.8%) and lithium 51 (20.4%) in 250 patients [ Figures 1 and 2 ].
Off-label drug use
Of 980 drugs, 387 (39.5%) drugs were prescribed in off-label manner. Of 250 patients, 198 (79.2%) of patients received at least one off-label drug according to BNF. Number of patients who received more than one off-label drugs as per BNF was was seen in 14 (5.6%) patients only. Prevalence of off-label use of clonazepam, lorazepam, and trihexyphenidyl HCl was significantly higher than other off label drugs as per BNF (P < 0.0001, P < 0.0001 and P < 0.0001, respectively). Most common category for off-label prescription was inappropriate indication. Increase in the number of drugs in prescription increases the chances to receive more number of off-label drugs, there was positive and significant correlation between off-label prescribing and number of drugs (Pearson correlation coefficient r = 0.722, P ≤ 0.000 for BNF). Age and off-label prescribing was not positively or significantly correlated (Pearson correlation coefficient r = 0.086, P = 0.173 for BNF). Off-label prescribing was statistically significantly higher in 21-40 year age group, but no difference was seen in any co-morbid condition or in between any psychiatric disorder.
Discussion
The aim of our study was to analyze the proportion of off-label prescribing based on BNF in Psychiatric Outpatient Department. Mean age of patients in our study was low as compared with earlier Indian outpatient study which reported 33.9 years. This slight difference might be due to geographical variation in study settings. [18] In our study, male:female ratio was 1.2:1 which was similar to other Indian studies study. [18, 19] In our study most common diagnosis was mood disorders, that is, major depressive disorder and bipolar disorder which was similar to earlier Indian outpatient study which also reported the same. [18] Mean number of drugs prescribed per patient in our study was 3.6 ± 1.42 which was higher as compared to previous Indian outpatient studies which reported 2.01 ± 1.03 this is due to difference in prescribing practices and different associated co-morbid conditions, [18] but this finding was in accordance to other Indian study focused on antidepressants drug utilization. [20] In our study multivitamins, laxatives and ranitidine were most commonly prescribed drug groups which is in accordance with 109 (43.6%). The psychopharmacological drug most frequently prescribed in off-label manner was clonazepam 31 (12.4%), lorazepam 30 (12%), and trihexyphenidyl HCl 25 (10%) as shown in Table 2 . Benzodiazepine was the most commonly prescribed group in off-label manner, which was seen in 106 (42.4%) patients. Off-label use of atypical antipsychotics Clonazepam  N03AE01  31  16  2  3  7  2  1  0  0  0  0  Lorazepam  N05BA06  30  10  2  0  6  1  11  0  0  0  0  Trihexiphenidyl HCl N04AA01  25  3  0  3  10  0  9  0  0  0  0  Diazepam  N05BA01  22  0  0  0  13  8  0  1  0  0  0  Sodium Valproate N03AG01  21  0  1  1  18  0  0  1  0  0  0  Oxcarbazepine  N03AF02  21  2  2  4  2  0  13  1  1  0  0  Nitrazepam  N05CD02  13  3  0  0  4  0  7  0  0  0  0  Propranolol  C07AA05  9  3  0  0  0  0  6  0  0  0  0  Risperidone  N05AX08  8  1  0  1  3  0  0  1  0  2  0  Escitalopram  N06AB10  8  5  1 Trihexiphenidyl HCL was used in bipolar disorder, obsessive compulsive disorder, and schizophrenia. The psychiatrists prescribe trihexyphenidyl as a prophylactic measure to decrease the incidence of extra-pyramidal reactions to anti-psychotic drug.
Newer drugs like oxcarbazepine were used for psychiatric conditions in off-label manner which was also seen in earlier studies. [28] Most common category for off-label prescription was inappropriate indication which was similar to UK study. [8] We did not come across any studies from India related to off-label drug use in outpatient settings. Hence, we could not compare our results with equivalent Indian studies. There were a few limitations of our study; we included prescription from Tertiary Care Teaching Hospital so result may not accurately reflect practice in other settings. Study period can be extended but was adequate considering prospective design.
There is a need to raise awareness of off-label prescribing problem among psychiatricians so as to improve the prescribing of drugs. As FDA states, clinicians can prescribe off-label or unlicensed drugs provided they are aware about the benefits of such prescribing in certain special conditions. To ensure that patients are not exposed to unnecessary risks, controlled psychiatric clinical trials are required for drugs to determine the most appropriate indications for a particular drug.
For future studies, we can use DRUGDEX database which gives summaries of evidence based information on both on and off label indications, into three important evaluation dimensions (1) efficacy (in four categories: "Effective," "evidence favors efficacy," "evidence is inconclusive," and "ineffective"), (2) strength of recommendation (in four categories: "Class I-recommended," "Class IIa-recommended in most cases," "Class IIb-recommended in some cases," and "Class III-not recommended," and (3) strength of evidence [in three graded categories: "A," (good RCT evidence) "B," (less consistent RCT evidence) and "C" (non-RCT forms of evidence)]. [29] 
Conclusion
Off-label drug prescribing is prevalent in Psychiatric Outpatient Department in our setup. Among psychiatric patients use of off label drugs is common. Clonazepam, lorazepam, and trihexyphenidyl HCL were found to be the most frequently used drugs in off label manner. There is a need to raise awareness among psychiatrists and to encourage evidence-based off-label drug use. Moreover, use of various drug formularies also can improve the prescribing for psychiatric patients. previous outpatient study from India, these drugs were given to counteract adverse effects associated with psychotropic drugs. [18] Diazepam was the most frequently prescribed drug followed by imipramine and lithium which was also evident in another local study which showed benzodiazepine was the most frequently prescribed drug. [19] Prevalence of patients who received at least one off-label drug as per BNF was 79.2%, out of which who received more than one off-label drugs as per BNF was 109 (43.6%).
In our study, out of 980 drugs, 387 (39.5%) drugs were prescribed in off-label manner according to BNF which was comparable (i.e., 36.6%) to a previous inpatient foreign study done in UK using BNF. [21] And when compared to outpatient UK study, it was lower which reported 50% prescriptions as off-label. [22] In our study, vitamin was the most common co-prescribed drug group. The drug most frequently prescribed in off-label manner was clonazepam 31 (12.4%), lorazepam 30 (12%), and trihexyphenidyl HCl 25 (10%) as per BNF.
Off-label prescribing pattern in our setup showed higher use of benzodiazepines as compared to atypical antipsychotics in other countries, this is due to difference in morbidity pattern as in our setup greater number of patients presented with depression and schizophrenia for which psychiatrist prescribed benzodiazepines for insomnia and attenuation of aggressive symptoms in schizophrenia patients, whereas in other setup anxiety disorder, attention deficit hyperactivity disorder, dementia, severe geriatric agitation, eating disorders, and substance abuse were more prevalent. [23] Benzodiazepines such as clonazepam, lorazepam, and diazepam were used in depression, mania, bipolar disorder, obsessive compulsive disorder in off label manner. Clonazepam is involved in the enhancement of anti-anxiety effects, anticonvulsant effects on subclinical epilepsy, augments in serotonin (monoamine synthesis) or diminish in serotonin receptor sensitivity mediated through the GABA system, and control in GABA activity. Low-dose, long-term treatment with clonazepam exhibits a prophylactic effect against recurrence of depression. Clonazepam is useful for treatment-resistant or protracted depression, as well as for acceleration of response to conventional antidepressants. [24] However, a systemic review of six randomized controlled clinical trial showed no added advantage of adding benzodiazepines to antidepressant drugs. [25, 26] Benzodiazepines were also used in schizophrenia as an off-label indication. A meta-analysis of 16 randomized controlled trials (RCTs) evaluated the efficacy of benzodiazepines. When BZDs added to antipsychotics, no evidence for added antipsychotic efficacy was seen. Therefore, benzodiazepines should be considered primarily for desired ultra-short-term sedation of acutely agitated patients but not for augmentation of antipsychotics in the medium-and longterm pharmacotherapy of schizophrenia and related disorders as seen in our study groups. [27] 
